Calliditas Therapeutics ABNASDAQ:CALT
- LAST PRICE17.7260
- TODAY'S CHANGE (%)-0.1190 (-0.6669%)
- Bid / Lots16.9500/ 1
- Ask / Lots18.1000/ 1
- Open / Previous Close17.2300 / 17.8450
- Day Range
- 52 Week Range
- Volume5,893
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CALT |
|---|---|---|
| 09:32 ET | 748 | 17.23 |
| 09:39 ET | 100 | 17.535 |
| 09:46 ET | 100 | 17.5 |
| 09:48 ET | 400 | 17.5638 |
| 10:06 ET | 100 | 17.82 |
| 12:44 ET | 100 | 17.94 |
| 12:53 ET | 1000 | 17.6362 |
| 01:13 ET | 161 | 17.8875 |
| 02:32 ET | 200 | 17.8799 |
| 04:00 ET | 200 | 17.726 |
Dec 1, 2023
Calliditas announces additions to the management team, from 3:21AM ET on Friday Dec 01, 2023 by Dow Jones
3:21AM ET on Friday Dec 01, 2023 by Dow JonesPress Release: Calliditas announces additions to the management team, from 3:21AM ET on Friday Dec 01, 2023 by Dow Jones
3:21AM ET on Friday Dec 01, 2023 by Dow Jones
Nov 30, 2023
Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome, from 2:49AM ET on Thursday Nov 30, 2023 by Dow Jones
2:49AM ET on Thursday Nov 30, 2023 by Dow Jones
Nov 27, 2023
DJ Calliditas Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 7:24AM ET on Monday Nov 27, 2023 by Dow Jones
7:24AM ET on Monday Nov 27, 2023 by Dow Jones
Nov 24, 2023
Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon(R) for the treatment of primary IgA nephropathy, from 3:11AM ET on Friday Nov 24, 2023 by Dow Jones
3:11AM ET on Friday Nov 24, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Calliditas Therapeutics AB | 523.5M | -11.0x | --- |
Assembly Biosciences Inc | 48.6M | -0.5x | --- |
NightHawk Biosciences Inc | 9.8M | -0.2x | --- |
Healthy Extracts Inc | 17.3M | -8.9x | --- |
Orexo AB | 50.8M | -2.5x | --- |
Bioquest Corp | 22.3M | -40.0x | --- |
Company Information
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
Contact Information
- Headquarters
- D5, Kungsbron 1,STOCKHOLM, Sweden 111 22
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Elmar Schnee
- Chief Executive Officer
- Renee Aguiar-Lucander
- Chief Financial Officer
- Fredrik Johansson
- President - North America
- Andrew Udell
- Vice President - Regulatory Affairs
- Frank Bringstrup
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $523.5M |
|---|---|
Revenue (TTM) | $113.6M |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-1.61 |
Book Value | --- |
P/E Ratio | -11.0x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -32.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
